March 22, 2007 -- Eisai of Japan will acquire privately held Morphotek of Philadelphia for $325 million; Adams Respiratory rose after settling a patent dispute with Mutual Pharma; PDI Inc. lost a $35 million contract to market a drug for an unnamed pharma; Pain Therapeutics in-licensed technology for hemophilia from researchers at Stanford; Peregrine reported positive early results from a Phase Ib trial of a cancer drug; Cubist out-licensed the Japanese rights for its antibiotic Cubicin to Merck; GPC Biotech gave additional details about the Phase III trial of prostate cancer drug satraplatin; and Bio Stem detailed how its acquisition of Cryobanks could develop $200 million in revenue. The Centient Biotech 200™ added on 8 points to close at 3931, a rise of .25%. More details...
